|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of the p38a-mapkap kinase 2 heterodimer
|
|
Structure:
|
 |
Mitogen-activated protein kinase 14. Chain: a, b. Synonym: mitogen-activated protein kinase p38 alpha, map kinase p38 alpha, cytokine suppressive anti-inflammatory drug-binding protein, csaid-binding protein, csbp, max-interacting protein 2, map kinase mxi2, sapk2a. Engineered: yes. Map kinase-activated protein kinase 2. Chain: c, d.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: mapk14, csbp, csbp1, csbp2, mxi2. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: mapkapk2.
|
|
Resolution:
|
 |
|
4.00Å
|
R-factor:
|
0.315
|
R-free:
|
0.331
|
|
|
Authors:
|
 |
E.Ter Haar
|
Key ref:
|
 |
E.ter Haar
et al.
(2007).
Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.
J Biol Chem,
282,
9733-9739.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
24-Jan-07
|
Release date:
|
06-Feb-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B:
E.C.2.7.11.24
- mitogen-activated protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
282:9733-9739
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.
|
|
E.ter Haar,
P.Prabakhar,
X.Liu,
C.Lepre.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The p38 signaling pathway is activated in response to cell stress and induces
production of proinflammatory cytokines. P38alpha is phosphorylated and
activated in response to cell stress by MKK3 and MKK6 and in turn phosphorylates
a number of substrates, including MAPKAP kinase 2 (MK2). We have determined the
crystal structure of the unphosphorylated p38alpha-MK2 heterodimer. The
C-terminal regulatory domain of MK2 binds in the docking groove of p38alpha, and
the ATP-binding sites of both kinases are at the heterodimer interface. The
conformation suggests an extra mechanism in addition to the regulation of the
p38alpha and MK2 phosphorylation states that prevents phosphorylation of
substrates in the absence of cell stress. Addition of constitutively active
MKK6-DD results in rapid phosphorylation of the p38alpha-MK2 heterodimer.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
FIGURE 1. Crystal structure of the p38 -MK2 heterodimer. A,
side view of the p38 -MK2 heterodimer. P38
(yellow) and MK2
(magenta) are positioned "face to face" in the heterodimer,
which means that the ATP-binding sites and the substrate binding
grooves are at the interface of the heterodimer. The K-helix
of the MK2 C-terminal regulatory domain (blue) is sandwiched
between the p38 and MK2 kinase domains,
whereas residues 370–393 of the C-terminal regulatory domain
bind p38 in the docking groove.
B, heterodimer rotated 180°. C, top view of the heterodimer.
|
 |
Figure 3.
FIGURE 3. Binding of MK2 C-terminal regulatory domain in
the p38 docking groove. The MK2
C-terminal regulatory domain binds both the common docking site
(A) and the ED site (B). The side chains of Ala^378, Ser^379,
Leu^384, and Lys^388 of MK2 have been omitted for clarity. The
side chains of p38 are colored yellow. MK2
is colored purple.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2007,
282,
9733-9739)
copyright 2007.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.Kostenko,
M.T.Khan,
I.Sylte,
and
U.Moens
(2011).
The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor.
|
| |
Cell Mol Life Sci,
68,
289-301.
|
 |
|
|
|
|
 |
A.Cuadrado,
and
A.R.Nebreda
(2010).
Mechanisms and functions of p38 MAPK signalling.
|
| |
Biochem J,
429,
403-417.
|
 |
|
|
|
|
 |
H.C.Reinhardt,
P.Hasskamp,
I.Schmedding,
S.Morandell,
M.A.van Vugt,
X.Wang,
R.Linding,
S.E.Ong,
D.Weaver,
S.A.Carr,
and
M.B.Yaffe
(2010).
DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization.
|
| |
Mol Cell,
40,
34-49.
|
 |
|
|
|
|
 |
R.Cheng,
B.Felicetti,
S.Palan,
I.Toogood-Johnson,
C.Scheich,
J.Barker,
M.Whittaker,
and
T.Hesterkamp
(2010).
High-resolution crystal structure of human Mapkap kinase 3 in complex with a high affinity ligand.
|
| |
Protein Sci,
19,
168-173.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.C.Reinhardt,
and
M.B.Yaffe
(2009).
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.
|
| |
Curr Opin Cell Biol,
21,
245-255.
|
 |
|
|
|
|
 |
M.A.Argiriadi,
S.Sousa,
D.Banach,
D.Marcotte,
T.Xiang,
M.J.Tomlinson,
M.Demers,
C.Harris,
S.Kwak,
J.Hardman,
M.Pietras,
L.Quinn,
J.DiMauro,
B.Ni,
J.Mankovich,
D.W.Borhani,
R.V.Talanian,
and
R.Sadhukhan
(2009).
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study.
|
| |
BMC Struct Biol,
9,
16.
|
 |
|
|
|
|
 |
S.B.Patel,
P.M.Cameron,
S.J.O'Keefe,
B.Frantz-Wattley,
J.Thompson,
E.A.O'Neill,
T.Tennis,
L.Liu,
J.W.Becker,
and
G.Scapin
(2009).
The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
|
| |
Acta Crystallogr D Biol Crystallogr,
65,
777-785.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Yoshizawa,
D.Hammaker,
D.L.Boyle,
M.Corr,
R.Flavell,
R.Davis,
G.Schett,
and
G.S.Firestein
(2009).
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression.
|
| |
J Immunol,
183,
1360-1367.
|
 |
|
|
|
|
 |
K.M.Sours,
S.C.Kwok,
T.Rachidi,
T.Lee,
A.Ring,
A.N.Hoofnagle,
K.A.Resing,
and
N.G.Ahn
(2008).
Hydrogen-exchange mass spectrometry reveals activation-induced changes in the conformational mobility of p38alpha MAP kinase.
|
| |
J Mol Biol,
379,
1075-1093.
|
 |
|
|
|
|
 |
S.Duraisamy,
M.Bajpai,
U.Bughani,
S.G.Dastidar,
A.Ray,
and
P.Chopra
(2008).
MK2: a novel molecular target for anti-inflammatory therapy.
|
| |
Expert Opin Ther Targets,
12,
921-936.
|
 |
|
|
|
|
 |
J.E.Clark,
N.Sarafraz,
and
M.S.Marber
(2007).
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.
|
| |
Pharmacol Ther,
116,
192-206.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |